Focusing on cytokine and inflammatory mediators within the whole signalling pathways between TNF-α, TRAIL, also known as Apo2 ligand, and NF-κB provides a comprehensive understanding of this complex pathway as it relates to breast and colon cancer and offers insight into potential therapeutic agents. This evidence concerns the gene TNF and colonic neoplasm.